The University of Texas MD Anderson Cancer Center is pleased to announce the appointment of George Wilding, MD, as Vice Provost for Clinical and Interdisciplinary Research, effective September 1.
Prior to joining MD Anderson, Dr. Wilding served on the institution’s external advisory board. He also served as Chair of the Moon Shots Program Scientific Advisory Board. The Moon Shots Program was launched in fall 2012 to accelerate the conversion of scientific discoveries into clinical advances and significantly reduce cancer deaths.
In his role at MD Anderson, Dr. Wilding will oversee strategic planning, conduct, approval, and regulation of all clinical research conducted at MD Anderson and its global operations. He will also provide oversight and academic leadership for its multidisciplinary research institutes.
“I am confident that Dr. Wilding’s professional expertise and leadership experience have prepared him for this vital role,” said Ethan Dmitrovsky, MD, MD Anderson Provost and Executive Vice President. “Additionally, his leadership approach and many other talents, including deep strategic thinking and thoughtfulness, will contribute substantially to our efforts to build upon our incredible foundation of critical clinical research advances.”
Dr. Wilding’s interests focus on genitourinary cancers, particularly prostate cancer. In addition to his administrative appointment, he will serve as Professor of Genitourinary Medical Oncology at MD Anderson.
His research interests concern the role of androgen-induced oxidative stress in prostate carcinogenesis and cancer progression. Two agents targeting this pathway for prostate cancer were developed in his laboratory. One of the agents has entered clinical testing, and the other is approaching this critical phase.
Dr. Wilding currently serves as the Donald and Marilyn Anderson Professor of Clinical Oncology at the University of Wisconsin School of Medicine and Public Health and Director Emeritus of the University of Wisconsin Carbone Cancer Center, Madison. ■
